Log In
Print this Print this

roledumab (R593)

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
DescriptionRecombinant human mAb against Rhesus D antigen
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II/III
Standard IndicationHemolytic disease
Indication DetailsPrevent Rhesus D hemolytic disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today